S-1226

Add links
Source: Wikipedia, the free encyclopedia.

S-1226, or S1226, is a mixture of carbon dioxide-enriched air and nebulized perflubron being developed as a novel bronchodilator for use in respiratory diseases such as asthma,[1] cystic fibrosis,[2] and COVID-19[3] by SolAeroMed.

Unlike typical bronchodilators such as

airways, clear excess mucus, and reduce inflammation. Thus, S-1226 represents a novel class of bronchodilators that could alleviate certain problems of existing therapeutics, such as the buildup of tolerance to their effects and their inefficient penetration of airway mucus.[1][4]

Clinical studies

Asthma

S-1226 has completed

asthma exacerbations caused by exposure to allergens
.

Phase I

The phase I randomized double-blind placebo-controlled trial designed to assess the safety of S-1226 compared 3 different formulations of S-1226 containing varying concentrations of carbon dioxide (4%, 8%, and 12%) to a placebo. No serious adverse events were reported, though S-1226 caused a greater number of related adverse events than did the placebo. These events were attributed by the investigators to the carbon dioxide constituent of S-1226.[1]

Phase II

The phase II randomized double-blind placebo-controlled

cross-over trial was designed to further assess the safety and to provide preliminary evidence of efficacy of S-1226 in treating acute asthma exacerbations caused by exposure to allergens. The 8% carbon dioxide formulation of S-1226 was used in this study due to its favourable efficacy in animal studies and favourable safety in the phase I trial. The trial enrolled 12 patients with mild allergic asthma who were randomised to either receive S-1226 (8% carbon dioxide) or placebo. After the first treatment period and a washout period of 14 days, the group initially randomised to S-1226 received placebo, and vice versa in the second treatment period.[4]

No serious adverse events were reported. The placebo group experienced a gradual lowering of

FEV1 (the volume of air a person can forcibly exhale in 1 second) more rapidly than the placebo group following allergen exposure.[4]

Cystic fibrosis

As of December 2023, SolAeroMed were recruiting patients with cystic fibrosis for a phase II trial of S-1226.[5]

References

  1. ^
    PMID 27464582
    .
  2. S2CID 245123442
    , retrieved 2023-12-15
  3. ^ "Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia | Reagan-Udall Foundation". reaganudall.org. Retrieved 2023-12-15.
  4. ^
    PMID 29914544
    .
  5. ^ "S1226 Lead Product | SolAeroMed I Leader in Biophysical Respiratory Drugs and Delivery Devices". Retrieved 2023-12-15.
Retrieved from "https://en.wikipedia.org/w/index.php?title=S-1226&oldid=1193047756"
This page is based on the copyrighted Wikipedia article: S-1226. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy